Want to see LADX full AI Analyst Report?
LADX Stock Chart & Stats
$0.02
$0.00(0.00%)
At close: 4:00 PM EST
$0.02
$0.00(0.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $2.20
Previous CloseN/A
Volume2.00
Average Volume (3M)1.01K
Market Cap
$5.45K
Enterprise Value-$153.97K
Total Cash (Recent Filing)$206.95K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-18.49
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.04
Shares Outstanding495,092
10 Day Avg. Volume91
30 Day Avg. Volume1,007
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.59
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-28.27
Enterprise Value/Revenue-22.24
Enterprise Value/Gross Profit-599.12
Enterprise Value/Ebitda0.04
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)204
Revenue Forecast (FY)$113.28M
Bulls Say, Bears Say
Bulls Say
Proprietary Technology PlatformsLadRx's focus on proprietary technology platforms provides a competitive edge in developing unique cancer therapeutics, potentially leading to successful commercialization and partnerships.
Partnership OpportunitiesLadRx's strategy of forming partnerships and licensing agreements with larger pharmaceutical companies can enhance its market reach and provide necessary financial support for R&D.
No DebtThe absence of debt provides LadRx with some financial flexibility, allowing the company to focus on strategic investments and partnerships without the burden of interest obligations.
Bears Say
Negative EquityNegative equity suggests that LadRx is facing financial distress, which could hinder its ability to invest in R&D and commercialize its drug candidates effectively.
Lack Of RevenueThe absence of revenue generation highlights the challenge LadRx faces in commercializing its projects, which is critical for sustaining operations and achieving profitability.
Board Member ResignationThe resignation of a board member can signal potential governance issues or strategic disagreements, impacting investor confidence and long-term strategic direction.
LadRx News
LADX FAQ
What was LadRx’s price range in the past 12 months?
LadRx lowest stock price was <$0.01 and its highest was $2.20 in the past 12 months.
What is LadRx’s market cap?
LadRx’s market cap is $5.45K.
When is LadRx’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were LadRx’s earnings last quarter?
Currently, no data Available
Is LadRx overvalued?
According to Wall Street analysts LadRx’s price is currently Overvalued.
Does LadRx pay dividends?
LadRx does not currently pay dividends.
What is LadRx’s EPS estimate?
LadRx’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LadRx have?
LadRx has 495,092 shares outstanding.
What happened to LadRx’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of LadRx?
Currently, no hedge funds are holding shares in LADX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
LadRx
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent that targets and delivers the chemotoxic agent to the tumor environment and release within the tumor. Its lead candidates comprising LADRs 7, 8, 9, and 10 with novel derivatives of the auristatin and maytansinoid drug targeting tumors; and aldoxorubicin, which is in phase II clinical development for the treatment of pancreatic cancer. In addition, the company develops albumin companion diagnostic (ACDx) to identify patients with cancer that benefits from treatment with the four LADR lead candidates. The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. The company was incorporated in 1985 and is headquartered in Los Angeles, California.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---